About: Racura Oncology Ltd operates as a clinical-stage biopharmaceutical company in Australia. It develops RC220, a formulation of (E,E)-bisantrene, which is in Phase III clinical trial for the treatment of acute myeloid leukemia; Phase Ia/b clinical trial for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer; and Phase Ia/b clinical trial for the treatment of solid tumor cancers. The company was formerly known as Race Oncology Limited and changed its name to Racura Oncology Ltd in December 2025. Racura Oncology Ltd was incorporated in 2011 and is headquartered in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$2.14 (-3.17%)
RACASXRace Oncology Ltd
Loading watchlist status…
Race Oncology Ltd share price
RAC price activity
Last Price
Change (24hr)
AUD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
RAC price performance
-0.47%
5D
9.74%
1M
-21.61%
YTD
54.51%
1Y
RAC price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
AU-ASX rank
N/ASector Rank
N/ARAC Market Signals